The way to effective prevention of cardiovascular complications: review
https://doi.org/10.15829/1728-8800-2024-4167
EDN: YWNXZD
Abstract
A descriptive review of modern Russian and foreign literature devoted to the polypill concept in internal medicine and cardiology practice is presented.
Methodology. The following databases were used in the search for information: PubMed, Scopus, Web of Science and Cochrane Library, as well as Russian databases, including eLIBRARY and CyberLeninka. The search used keywords and phrases such as "polypill", "combination therapy", "cardiovascular diseases", "adherence", "polycomponent drugs" and their analogues in English and Russian. Particular attention was paid to studies published over the past 15 years, with an emphasis on studies conducted over the past 5 years to reflect current trends and innovations in the use of polypills.
Results. Clinical evidence of the benefits of fixed-dose combinations allows the implementation of the polypill strategy in practice and to achieve maximum reduction of cardiovascular risk.
Conclusion. Novel drug combinations have already been developed and are available for use. They need to be introduced so that the therapy is most adapted for many patients and effective in achieving different therapeutic goals in internal medicine and cardiology practice.
Keywords
Supporting agencies: The study was supported by the pharmaceutical company KRKA.
About the Authors
L. D. Khidirova
Novosibirsk State Medical University; Novosibirsk Regional Clinical Cardiology Dispensary
Russian Federation
Russian Federation
Novosibirsk
S. G. Zakoryukina
Novosibirsk State Medical University
Russian Federation
Russian Federation
Novosibirsk
References
1. Muromtseva GA, Kontsevaya A, Konstantinov V, et al. Prevalence of risk factors for noncommunicable diseases in the Russian population in 2012-2013. The results of the ESSAY-RF study. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi:10.15829/1728-8800-2014-6-4-11.
2. Boytsov S, Balanova Yu, Shalnova SA, et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. by the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) doi:10.15829/1728-8800-2014-4-4-14.
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population representative studies with 104 million participants. Lancet 2021;398:957-80. doi:10.1016/S0140-6736(21)01330-1.
4. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. BMC Medicine. 2013;11(1):177. doi:10.1186/1741-7015-11-177.
5. Piepoli MF, Hoes AW, Agewall S, et al.; ESC Scientific Document Group. 2016 European Guidelineson cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special-contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-81. doi:10.1093/eurheartj/ehw1062017.
6. Roth G, Murray K, Nagavi N, et al. Death Cause Collaborator. Global, regional, and national age-specific mortality rates for 282 causes of death in 195 countries and territories in 1980-2017: Systematic analysis of global disease burden research in 2017. Lancet. 2018;392(10159):1736-88. doi:10.1016/s140-6736(18)32203-7.
7. Ezhov MV, Kuharchuk VV, Sergienko IV, et al. Disorders of lipid metabolism. Clinical guidelines. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) doi:10.15829/1560-4071-2023-5471.
8. Gorokhova TV, Perepech NB. Potential of combination therapy in patients with hypertension and dyslipidemia. Russian Journal of Cardiology. 2022;27(7):5132. (In Russ.) doi:10.15829/1560-4071-2022-5132.
9. Drapkina OM, Vavilova TV, Karpov YuA, et al. The resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelines. Cardiovascular Therapy and Prevention. 2022;21(12):3487. (In Russ.) doi:10.15829/1728-8800-2022-3487.
10. Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA. 2015;313:603-15. doi:10.1001/jama.2014.18574.
11. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318. doi:10.1136/bmj.g.3318.
12. Brainin M, Teuschl Y, Martins S. Polypill: Benefits Seen for Stroke and Other Outcomes. Stroke. 2022;53(8):2695-701. doi:10.1161/STROKEAHA.122.037313.
13. Matusitz J, Spear J. Effective communication between doctor and patient: an updated examination. Soc Works Field Public Health. 2014;29(3):252-66. doi:10.1080/19371918.2013.776416.
14. Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. International Polycap Study 3 Investigators. N Engl J Med. 2021;384(3):216-28. doi:10.1056/NEJMoa2028220.
15. Khidirova LD, Yakhontov DA, Madonov PG. Assessment of adherence to therapy in comorbid patients. Arterial hypertension. 2023;29(1):109-18. (In Russ.) doi:10.18705/1607-419X-2022-28-6-109-118.
16. Lebedev PA, Garanin AA. From Low-Dose Fixed Combinations for Arterial Hypertension Treatment to Multi-Target Therapy of Cardiovascular Diseases. Rational Pharmacotherapy in Cardiology. 2020;16(4):638-43. (In Russ.) doi:10.20996/1819-6446-2020-08-03.
17. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22(7):920-30. doi:10.1177/2047487314530382.
18. Kobalava ZhD, Kohan EV. Arterial'naya gipertoniya i giperholesterinemiya: vremya anti-"lipotenzivnoj" terapii? Rational Pharmacotherapy in Cardiology. 2020;16(5):842-51. (In Russ.) doi:10.20996/1819-6446-2020-09-01.
19. Gilyarevskij SR, Bendeliani NG, Golshmid MV, et al. The application of combined preparations with constant doses of antihypertensive drugs as the initial tactics of treatment at high blood pressure level: proven facts and expert’s opinion. Eurasian Heart Journal. 2021;(2):92-102. (In Russ.) doi:10.38109/2225-1685-2021-2-92-102.
20. Baryshnikova GA, Chorbinskaya SA, Stepanova II, et al. Polypillule as a means of effective treatment of patients with high cardiovascular risk. Difficult patient. 2019;7(3):22. (In Russ.) doi:10.26442/2075-1753_19.10.13-18.
21. Sokolova AA, Napalkov DA. Optimal treatment strategies in comorbid patients with hypertension and dyslipidemia: the role of fixed-dose combinations. Russian Journal of Cardiology. 2023;28(12):5712. (In Russ.) doi:10.15829/1560-4071-2023-5712.
22. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339.
23. Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill Strategy in Secondary Cardiovascular Prevention. SECURE Investigators. N Engl J Med. 2022;387(11):967-77. doi:10.1056/NEJMoa2208275.
24. Konradi AO, Alieva AS. Hypertension and dyslipidemia. Parallel risk factor control: role of fixed combination. Arterial Hypertension. 2021;27(3):376-83. (In Russ.) doi:10.18705/1607-419X-2021-27-3-376-383.
25. Henavi HA, Sharaf MT, Zohaib M. Polypilular therapy in cardiovascular diseases: a meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023;48(8):101735. doi:10.1016/j.cpcardiol.2023.101735.
26. Joseph P, Prem P, Dans A, et al. The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. 2018;206:72-9. doi:10.1016/j.ahj.2018.07.012.
27. Castellano JM, Sanz G, Peñalvo JL, et al. Polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071-82. doi:10.1016/j.jacc.2014.08.021.
28. Lonn E, Bosch J, Pogue J, et al. HOPE-3 researchers. New approaches to the primary prevention of cardiovascular diseases: the rationale for the HOPE-3 study, design and initial characteristics of the participants. doi:10.1016/j.cjca.2015.07.001.
29. Webster R, Bullen C, Patel А, еt al. The effect of switching to polypill-based therapy on the initial efficacy of the drug: Post-hoc analysis of the SPACE Collaboration dataset. Cardiology. 2017;13:443-7. doi:10.1016/j.ijcard.2017.09.162.
30. Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918-29. doi:10.1001/jama.2013.277064.
31. Selak V, Ellie KR, Krengle S, et al. Treatment adherence with combination therapy (IMPACT): design and protocol of a randomized controlled trial in primary care. Contemp Clin Tests. 2011;32(6):909-15. doi:10.1016/j.cct.2011.07.006.
32. Liu H, Patel A, Brown A, et al; Vascular Kanyini Collaboration; Research the Kanyini GAP band. Rationale and design of Kanini's recommendations for compliance in the Kanyini-GAP study: a randomized controlled trial of a polypill-based strategy among indigenous and non-indigenous peoples at high risk of cardiovascular disease. BMC Public Health. 2010;5(10):458. doi:10.1186/1471-2458-10-458.
33. Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Arterial'naya gipertenziya u vzroslyh. Klinicheskie rekomendacii 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) doi:10.15829/1560-4071-2020-3-3786.
34. Khidirova LD, Shpagina LA, Shpagin IS, et al. Actual problems of pharmacotherapy in comorbid patients with arterial hypertension and chronic obstructive pulmonary disease. Atmosphere. Cardiology News. 2023;1:22-8. (In Russ.) doi:10.24412/2076-4189-2023-12838.
35. Аbramov NV, Kashtalap VV, Semenihin VA. The role of polytablets (polypill) in the treatment of chronic cardiovascular diseases. Medicine in Kuzbass. 2024;1:11-4. (In Russ.) doi:10.24412/2687-0053-2024-1-11-14.
Supplementary files
What is already known about the subject?
- A polypill is a combination of several drugs in one pill.
- The Heart Outcomes Prevention Evaluation-3 (HOPE-3) study demonstrated that the use of combination therapy in patients with a moderate risk level reduces the incidence of major cardiovascular events.
- The Secondary Prevention of Cardiovascular Disease in the Elderly (SECURE) study showed that the use of a polypill in post-infarction therapy reduces mortality and the risk of recurrent cardiovascular events.
What might this study add?
- Our results confirm the data on fixed-dose combination therapy for hypertension using the polypill concept to achieve the necessary clinical outcomes and reduce the risk of cardiovascular events, which is presented in the SPACE project.
- The introduction of polypills into clinical practice for the prevention of recurrent events is supported and complemented by the results of the following studies: The International Polycap Study 3 (TIPS-3), Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE), Improving Adherence using Combination Therapy (IMPACT) and Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) studies. The efficacy and safety of polypills in various populations has also been proven.
- Polypills significantly increase medication adherence according to the following randomized clinical trials: Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention (FOCUS) and Improving Adherence using Combination Therapy (IMPACT).
Review
For citations:
Khidirova L.D., Zakoryukina S.G. The way to effective prevention of cardiovascular complications: review. Cardiovascular Therapy and Prevention. 2024;23(10):4167. (In Russ.) https://doi.org/10.15829/1728-8800-2024-4167. EDN: YWNXZD
Views:
293
Email this article 
